Literature DB >> 35110860

Medium-chain Triglyceride Ketogenic Diet as a Treatment Strategy for Adult Super-refractory Status Epilepticus.

Kaustuv Dutta1, Parthasarathy Satishchandra2, Monjuri Borkotokey3.   

Abstract

How to cite this article: Dutta K, Satishchandra P, Borkotokey M. Medium-chain Triglyceride Ketogenic Diet as a Treatment Strategy for Adult Super-refractory Status Epilepticus. Indian J Crit Care Med 2022;26(1):139-140.
Copyright © 2022; The Author(s).

Entities:  

Keywords:  Classic ketogenic diet; Hypoxic-ischemic brain injury; Medium-chain triglyceride ketogenic diet; Refractory status epilepticus; Super-refractory status epilepticus

Year:  2022        PMID: 35110860      PMCID: PMC8783258          DOI: 10.5005/jp-journals-10071-24073

Source DB:  PubMed          Journal:  Indian J Crit Care Med        ISSN: 0972-5229


Dear Sir, Super-refractory status epilepticus (SRSE) may be defined as status epilepticus (SE) that persists for 24 hours or more after the commencement of anesthetic medications or recurs after termination of anesthesia.[1] An emerging treatment modality for SRSE is ketogenic diet (KD), of which the two main types are classic KD (CKD) and the medium-chain triglyceride KD (MCTKD).[2,3] Although MCTKD has many advantages over CKD, published data evaluating the effect of MCTKD in adult SRSE are very sparse. We report a case of an adult SRSE successfully treated with MCTKD. A 35-year-old woman underwent elective lower segment caesarean section (LSCS) at 38 weeks of gestation. About 3 hours postoperatively, she developed sudden onset breathing difficulty, followed by cardiac arrest. She was resuscitated and transferred to the intensive care unit (ICU) where she developed generalized tonic-clonic seizures (GTCS), which failed to respond to lorazepam. In view of uncontrolled seizures, she was shifted to our center for further management. Hypothermia was initiated and maintained for the next 24 hours. Both intravenous and enteral antiepileptic drugs (AEDs) were gradually added. However, she continued to have segmental myoclonic jerks involving extremities despite midazolam infusion. The patient was on six AEDs including, injections levetiracetam, valproate, topiramate, lacosamide, and tablets clobazam and perampanel. Ketamine infusion @ 5 mg/kg/hour was started. This helped to achieve burst suppression but electrographic seizures appeared with every attempt to decrease the anesthetic drugs (Fig. 1). MRI brain revealed moderate-to-severe hypoxic brain injury. The patient was diagnosed as a case of SRSE due to hypoxic-ischemic brain injury (HIBI). Initiation of KD was considered on the 14th day of admission (day 0). Lipid profile and serum electrolytes were found to be normal. Urinary ketosis was achieved on day 3. Following this, MCTKD was initiated. The Ryles tube feeds consisted of sugar free soya milk with MCT oil. The myoclonic jerks reduced significantly by day 5 and stopped completely by day 10. The glucose, serum electrolytes, arterial blood gas, triglycerides, and urinary ketosis were closely monitored during this period. She was weaned off the midazolam and ketamine infusion by day 12 and maintained on five AEDs without seizure. She was weaned off the ventilator on day 15 and referred to a neurorehabilitation center. The MCTKD was continued for 3 months without any significant adverse effects, except for a weight loss of around 5 kg.
Fig. 1

EEG showing generalized and focal epileptiform activity with spikes and polyspike and wave activity along with diffuse slow background

EEG showing generalized and focal epileptiform activity with spikes and polyspike and wave activity along with diffuse slow background SRSE poses a serious challenge to the treating intensivists. The high mortality and morbidity associated with the condition increase the need for safe and effective treatment modalities. KD is a diet having high fat with low carbohydrate and protein content, typically in the ratio of 3:1 or 4:1. MCTKD is more ketogenic and allows larger carbohydrate and protein portions, making it more appetizing.[4] Compared to CKD, which is associated with persistent hypertriglyceridemia, MCTKD is associated with significantly lower total cholesterol/high-density lipoprotein (HDL) ratios as it is metabolized faster.[3,4] Prasoppokakorn et al. reported the first successful treatment of adult SRSE using MCTKD.[3] It has been postulated that MCTKD can increase seizure threshold and stop the onset of seizures by direct inhibition of AMPA receptors and alteration of cellular energetics through mitochondrial biogenesis.[5] To best of our knowledge, this is the first report of successful treatment of SRSE due to HIBI using MCTKD from India. Our patient showed almost total resolution of seizure without any significant adverse effects. This suggests that MCDKD can be a safe and feasible treatment option for SRSE in adults due to HIBI.

Orcid

Kaustuv Dutta https://orcid.org/0000-0002-5749-3761 Parthasarathy Satishchandra https://orcid.org/0000-0003-4334-1342 Monjuri Borkotokey https://orcid.org/0000-0002-9890-7561
  5 in total

1.  Medium-chain triglyceride ketogenic diet is effective for treatment of an adult with super-refractory status epilepticus: a case report and literature review.

Authors:  Thaninee Prasoppokakorn; Suda Jirasakuldej; Narisorn Lakananurak
Journal:  Eur J Clin Nutr       Date:  2019-07-17       Impact factor: 4.016

2.  Ketogenic diet for adults in super-refractory status epilepticus.

Authors:  Kiran T Thakur; John C Probasco; Sara E Hocker; Kelly Roehl; Bobbie Henry; Eric H Kossoff; Peter W Kaplan; Romergryko G Geocadin; Adam L Hartman; Arun Venkatesan; Mackenzie C Cervenka
Journal:  Neurology       Date:  2014-01-22       Impact factor: 9.910

Review 3.  Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets.

Authors:  Yeou-mei Christiana Liu; Huei-Shyong Wang
Journal:  Biomed J       Date:  2013 Jan-Feb       Impact factor: 4.910

Review 4.  The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy.

Authors:  Monica Ferlisi; Simon Shorvon
Journal:  Brain       Date:  2012-05-09       Impact factor: 13.501

Review 5.  Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders.

Authors:  Katrin Augustin; Aziza Khabbush; Sophie Williams; Simon Eaton; Michael Orford; J Helen Cross; Simon J R Heales; Matthew C Walker; Robin S B Williams
Journal:  Lancet Neurol       Date:  2017-12-16       Impact factor: 44.182

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.